Cargando…

Hepatitis B Co-Infection Has Limited Impact on Liver Stiffness Regression in Chronic Hepatitis C Patients Treated with Direct-Acting Antivirals

Introduction: High sustained virological response (SVR) rate (>95%) and liver stiffness regression can be achieved with direct acting antivirals treatment (DAA) in patients with chronic hepatitis C virus (CHC) infection. Reactivation of hepatitis B virus (HBV) was reported during DAA treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Cheng-Er, Liu, Yen-Chun, Cheng, Ya-Ting, Jeng, Wen-Juei, Chien, Rong-Nan, Lin, Chun-Yen, Tai, Dar-In, Sheen, I-Shyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024676/ https://www.ncbi.nlm.nih.gov/pubmed/35458516 http://dx.doi.org/10.3390/v14040786

Ejemplares similares

Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients
por: Liu, Yen-Chun, et al.
Publicado: (2020)

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis
por: Hsieh, Yi-Chung, et al.
Publicado: (2018)

A global perspective on hepatitis B‐related single nucleotide polymorphisms and evolution during human migration
por: Tai, Dar‐In, et al.
Publicado: (2017)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

The 2020 Nobel Prize in medicine for the discovery of hepatitis C virus: An epic saga of the fight against a troublesome virus
por: Lin, Chun-Yen, et al.
Publicado: (2021)

IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection
por: Lin, Chun-Yen, et al.
Publicado: (2011)

Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
por: Chiu, Shao-Ming, et al.
Publicado: (2020)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
por: Chen, Yi-Cheng, et al.
Publicado: (2020)

Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients
por: Teng, Wei, et al.
Publicado: (2021)

Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction
por: Hu, Ching-Chih, et al.
Publicado: (2017)

In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival
por: Huang, Chien-Hao, et al.
Publicado: (2019)

None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis
por: Jeng, Wen-Juei, et al.
Publicado: (2012)

Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma
por: Cheng, Ya-Ting, et al.
Publicado: (2016)

Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs
por: Ridziauskas, Martynas, et al.
Publicado: (2021)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Evolution of ferritin levels in hepatitis C patients treated with antivirals
por: Chang, Ming-Ling, et al.
Publicado: (2020)

Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents
por: Chen, Yen-Chun, et al.
Publicado: (2020)

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
por: Lee, Shou-Wu, et al.
Publicado: (2018)

Soluble form of CTLA‐4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients
por: Teng, Wei, et al.
Publicado: (2022)

Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization
por: Lin, Po-Ting, et al.
Publicado: (2022)

The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
por: Jeng, Wen-Juei, et al.
Publicado: (2023)

CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV
por: Lin, Chia-Chen, et al.
Publicado: (2017)

Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
por: Cheng, Pin-Nan, et al.
Publicado: (2019)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
por: Chen, Yen-Chun, et al.
Publicado: (2022)

Predictors of Mortality Within 6 Weeks After Treatment of Gastric Variceal Bleeding in Cirrhotic Patients
por: Teng, Wei, et al.
Publicado: (2014)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Increased EMR2 expression on neutrophils correlates with disease severity and predicts overall mortality in cirrhotic patients
por: Huang, Chien-Hao, et al.
Publicado: (2016)

Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis
por: Chang, Ming-Ling, et al.
Publicado: (2008)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
por: Pan, Jason J., et al.
Publicado: (2018)

Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
por: Chen, Chun-Hsien, et al.
Publicado: (2019)

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
por: Piedade, Juliana, et al.
Publicado: (2021)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
por: Wu, I-Chin, et al.
Publicado: (2021)

Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients
por: Cheng, Chun-Han, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6n7ld9k08m5a937664mp0c3qem